SCHEMBL975666

SCHEMBL975666

O=C(NO)c1ccccc1-c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.67
CHRNB4 P30926 4/20 0.67
CHRNA3 P32297 4/20 0.67
CHRNA4 P43681 4/20 0.67
HDAC7 Q8WUI4 3/20 0.64
BCAT2 O15382 1/20 0.59
ALDH1A1 P00352 3/20 0.57
HTT P42858 2/20 0.57
GAA P10253 2/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
LMNA P02545 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
KDM4E B2RXH2 1/20 0.55
MPO P05164 1/20 0.55
HIF1A Q16665 1/20 0.55
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8089215 0.96 CHRNB2 (0.62) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL27460658 0.94 HDAC7 (0.67) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL12922045 0.92 HDAC7 (0.60) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL12922053 0.87 HDAC8 (0.59) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL3026631 0.87 GAA (0.64) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL974404 0.85 SLC6A3 (0.63) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL14880211 0.85 HNF4A (0.68) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL13845096 0.85 HDAC7 (0.66) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL29256186 0.83 HDAC7 (0.59) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7
SCHEMBL27471401 0.83 HDAC7 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275536-A1 Antimicrobial Composition KAMER, Patrick (CH) 2025-09-04 US claimed
EP-4518653-A1 ANTIMICROBIAL COMPOSITION Kamer, Patrick (CH) 2025-03-12 EP claimed
WO-2023213846-A1 ANTIMICROBIAL COMPOSITION KAMER PATRICK (CH) 2023-11-09 WO claimed
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2011-01-27 US claimed
EP-2217588-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-08-18 EP claimed
WO-2009055917-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-05-07 WO claimed
US-20250275536-A1 Antimicrobial Composition KAMER, Patrick (CH) 2025-09-04 US disclosed
EP-4518653-A1 ANTIMICROBIAL COMPOSITION Kamer, Patrick (CH) 2025-03-12 EP disclosed
US-20240109847-A1 HISTONE DEACETYLASE INHIBITORS THE UNIVERSITY OF QUEENSLAND (AU) 2024-04-04 US disclosed
WO-2023213846-A1 ANTIMICROBIAL COMPOSITION KAMER PATRICK (CH) 2023-11-09 WO disclosed
EP-3239143-B1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEMICAL LTD (KR) 2023-03-22 EP disclosed
WO-2022133551-A1 HISTONE DEACETYLASE INHIBITORS THE UNIVERSITY OF QUEENSLAND (AU) 2022-06-30 WO disclosed
CN-107410317-A Improve the diffusible wet tissue composition in wet tissue fabric and the wet tissue containing said composition 明进新科技股份有限公司 2017-12-01 CN disclosed
WO-2000056300-A2 SYNTHESIS AND STRUCTURE OF METALLOCENE COMPOUNDS AND THEIR INTERACTIONS WITH LIPID MEMBRANES PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed
EP-0874808-A1 BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES Abbott Laboratories (US) 1998-11-04 EP disclosed
WO-1998008904-A1 ELECTRODEPOSITABLE COATING COMPOSITIONS CONTAINING HYDROXAMIC ACID AND DERIVATIVES THEREOF, AND THEIR USE IN A METHOD OF ELECTRODEPOSITION PPG INDUSTRIES, INC. (US) 1998-03-05 WO disclosed
US-5665777-A ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1997-09-09 US disclosed
WO-1997018188-A1 BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 1997-05-22 WO disclosed
US-4009116-A Process of preparing substantially organic waste liquids containing radioactive or toxic substances for safe, non-pollutive handling, transportation and permanent storage BAYER AKTIENGESELLSCHAFT (DT) 1977-02-22 US disclosed
US-3960762-A Production of absorbents BAYER AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021771-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC3 CHRNB2 2327/4885CHRNB4 2355/4885CHRNA3 1459/4885
US-20250275536-A1 Antimicrobial Composition CUTA, POLR1C, PIK3C3 CHRNB2 4802/4885CHRNB4 4790/4885CHRNA3 4736/4885
US-20240109847-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC11 CHRNB2 2882/4885CHRNB4 3749/4885CHRNA3 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.